RELMADA THERAPEUTICS, INC. Net Income (Loss) Attributable to Noncontrolling Interest
RELMADA THERAPEUTICS, INC. (RLMD) reported Net Income (Loss) Attributable to Noncontrolling Interest of -$39.75 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-05.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2022-05-05
- RELMADA THERAPEUTICS, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2022-03-31 was -$39.75M.
- RELMADA THERAPEUTICS, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2021-03-31 was -$22.22M.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month |
|---|---|
| 2022-03-31 | -$39.75M 10-Q · filed 2022-05-05 |
| 2021-03-31 | -$22.22M 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |